Every year on June 27, the World Microbiome Day brings global attention to the billions of microbes that live on our body. While many associate microbiomes to gut health and digestion, this limited understanding is insufficient for the current state of scientific knowledge on the importance of the microbiome. After two decades of microbiome research from large projects like the NIH Human Microbiome project, the microbiome has been understood to influence immunity, the brain, the skin, the reproductive system and athletic performance.
The emerging interest in applications of microbiome research beyond gut health presents a genuine commercial opportunity for those developing products, brand owners and clinical sponsors. With time, there will be more of a requirement for well-conducted clinical research capable of translating the discovered correlations into verifiable and defensible claims. This article discusses the emerging opportunities in microbiome research, which body systems attract the most research attention today and how to prepare for conducting microbiome clinical trials.
World Microbiome Day provides scientists, universities, and industry groups an opportunity to share new insights every year and remind the world that science of microorganisms exceeds gut health. For sponsors watching the category, every year this day comes as a perfect time to reflect how far microbiome research has advanced beyond gut health and to also check whether their strategy for development and evidence is aligned with the present research on microbiome.
Table of Contents
Why Microbiome Research Is Moving Beyond Gut Health
The gut is the most researched and possibly the most significant component of the human microbiome. This is because of its size, accessibility, and involvement in metabolic processes and immune functions. However, the current microbiome research extends beyond the digestive tract. It involves biologists examining microbial ecosystems inhabiting the skin, the genital tract, airways, and even tissue environments considered sterile before.
The expansion has its commercial benefits as it relates to various consumer and pharmaceutical categories. The sponsors are increasingly interested in microbiome-related studies concerning:
- Functional foods and nutraceutical products that would prove prebiotic, probiotic or postbiotic effects;
- Skin care and cosmetic products investing in microbiome-friendly formula;
- Women’s health products focusing on the vaginal microbiome health;
- Metabolic health solutions addressing glucose regulation and weight management;
- Immune-support products, particularly those targeting gut-immune axis;
- Digital health tools and diagnostics leveraging microbiome data as biomarkers.
Key Microbiome Research Areas Creating Emerging Opportunities for Sponsors
Gut-Immune Axis
The immune system functions associated with the gut microbiome represent one of the most promising areas of microbiome research. Approximately 70% of immune cells of our body are present in the gut, and the composition of the microbial populations is responsible for affecting how the immune system responds, the inflammatory tone and susceptibility to infections.
Sponsors that are making immune support-based products are becoming interested in validating claims through this axis. Microbiome clinical trials for sponsors usually use immune biomarkers like secretory IgA and natural killer cell activity, inflammatory parameters such as C-reactive protein and interleukin-6, the incidence of common respiratory diseases, gut microbiome profile, and self-reports of wellbeing by patients.
Science in this field is rapidly evolving. Research has shown that gut microorganisms synthesize metabolites, particularly short chain fatty acids (SCFAs), which aid in regulation of both innate and adaptive immunity. Immune biomarkers from successful microbiome clinical trials can be increasingly demonstrated by sponsors and will set them apart competitively.
Gut-Brain Axis
Apart from gut health, another branch of microbiome research that has received scientific interest is the gut-brain axis. A paper published in 2025 in the journal Frontiers in Aging Neuroscience describes the gut-brain axis a bidirectional network that allows gut microbes to affect one’s emotional and cognitive state.
The Enterochromaffin Cells present in the gut produce around 90% of the body’s serotonin, which helps in mood regulation. Serotonin is transmitted to the brain through the vagus nerve. The gut microbiome also produces other neuroactive chemicals including GABA and influence tryptophan metabolism.
The potential advancements in microbiome science are significant for the sponsors concerned with cognitive functioning, stress, mood, and sleep. A 2025 systematic review revealed that the interventions involving the manipulation of the microbiota lead to significant changes in neuroinflammation, cognitive functioning, and mood among humans. In this area, potential microbiome clinical trial endpoints may include validated tools for assessing mood and stress like DASS-21 and PSS, evaluation of cognitive functioning, assessment of sleep quality, quality of life measures, microbiome composition, and biomarkers of inflammation like CRP or cortisol.
Skin Microbiome
Apart from serving as a protective layer, the skin houses a thriving and dynamic microbial ecosystem that assist in maintaining the strength of the skin barrier, keeping it hydrated, and providing an immune response. In case this microbial population gets affected through a phenomenon called dysbiosis, the skin could be affected by inflammatory skin conditions like acne, atopic dermatitis and psoriasis.
Skin microbiome clinical research for cosmetics, dermocosmetics, and dermatology-based products are rapidly emerging as an important point of differentiation for the sponsors. A 2026 study published in the journal Skin Research and Technology observed that there is a great potential for skin microbiome studies to improve health conditions. However, evidence for cosmetics targeting the microbiome is still in its early stages.
The endpoints of microbiome clinical trials conducted often include both quantifiable results and self-assessments of subjects. Commonly used endpoints include skin hydration (corneometry measurements), transepidermal water loss (TEWL), skin barrier performance assessments, sebum level, signs of erythema or sensitivity, skin microbiome profile, and skin tolerability of the participants.
In a 2025 study published in Frontiers in Cellular and Infection Microbiology, skin microbial analysis was evaluated along with biophysical parameters. The authors showed that TEWL, sebum secretion, and skin hydration were significantly related to shifts in skin microbial communities. This provides an effective method for evaluating the impact of products on skin health.
Metabolic Health and Weight Management
There have been several discoveries made regarding metabolic health from microbiome clinical research. Gut microbes influence our body’s ability to process glucose and lipids, our energy balance, and appetite. This occurs by SCFA’s interaction with our body’s hormones such as GLP-1 and Peptide YY.
A 2025 analysis published in the International Journal of Molecular Sciences discovered that SCFAs, (butyrate, propionate, and acetate) affect fat gain, insulin sensitivity, and inflammation, with targeted SCFA supplementation showing improvements in insulin sensitivity and reductions in inflammatory markers. An analysis published in the American Journal of Clinical Nutrition in 2024 revealed that chicory inulin-type fructan supplementation caused an average weight loss of −0.97 kg among 32 randomized trials. An analysis of 100 studies in 2026 indicated that fecal microbiota transplantation from lean donors increased insulin sensitivity by 25% and reduced hemoglobin A1c levels by 0.6%.
The microbiome clinical trials for sponsors working on functional foods, nutraceuticals, and metabolic health should incorporate specific microbiome endpoints in clinical trials. This should be alongside metabolic biomarkers like glucose metabolism, insulin resistance, lipid panel, body composition, appetite, feeling of fullness, microbiome composition, and SCFAs.
Women’s Health and the Vaginal Microbiome
One key field for emerging opportunities in microbiome research is women’s health, specifically the vaginal microbiome. A 2025 review article in Frontiers in Cellular and Infection Microbiology noted that while there have been major advances in microbiome research, the primary focus has been on the gut microbiome. The article argued that vaginal microbiome holds significant potential in improving women’s health.
Healthy vaginal microbiota consists predominantly of Lactobacillus crispatus, that maintains the protective acidifying conditions and suppresses any pathogenic bacteria. In a 2025 placebo-controlled trial published in the journal Biofilms and Microbiomes, a multi-strain vaginal synbiotic was proven to induce L. crispatus dominance in the microbiome of 90% of subjects compared to only 11% in the control group.
For sponsors of intimate care products for women as well as probiotic formulations, the essential microbiome endpoints in clinical trials are vaginal microbiome composition, vaginal pH, symptom assessments such as Nugent score and vaginal health index, vaginal bacterial vaginosis recurrence rate, and quality of life measures and comfort self-reports by the participants.
Sports, Recovery, and Human Performance
Gut microbiota is increasingly significant to exercise adaptation, recovery and performance. The gut microbiome impacts how the body utilizes energy, training-induced inflammation responses and GI tolerance during exercise. For sponsors of sports nutrition and recovery products, microbiome clinical trials in this area have become increasingly practical. The outcomes from such trials may include exercise performance measures like VO₂ max, recovery markers like creatine kinase, muscle soreness, inflammatory responses, GI tolerance and gut microbiota at certain periods during training. Intensive training temporarily compromises immunity and increases susceptibility to infections. These are outcomes where probiotic interventions have demonstrated meaningful clinical benefit.
Why Clinical Evidence Is Critical for Microbiome-Based Claims
Microbiome research is very promising although that is not enough. Merely establishing the relationship between some microbial signature and an effect on health does not prove that the product under study has changed the outcome, or that the change is clinically meaningful. This is where well-designed microbiome clinical trials become essential. Several factors should guide sponsors approaching this space. This includes:
Microbiome associations do not automatically prove product efficacy: Although being able to show that the product affects the composition of the microbiome is scientific proof, it does not mean that the product is able to deliver its intended effect on the body.
Product claims require measurable outcomes: Whether a claim is related to immunity, digestive comfort, skin condition, or weight control, it should be backed up by an endpoint that directly reflects the proposed benefit. Regulating agencies, including EFSA for Europe and FDA for the United States, demand that any health claim be evidence-based.
Clinical benefits should be linked to relevant endpoints: Sponsors should work with the clinical research experts so that the proposed claims can be associated with the appropriate primary and secondary endpoints before the study begins. The attempt to identify an outcome from the data post study is rarely justified.
Microbiome data should be interpreted alongside symptoms, biomarkers, and participant-reported outcomes: Microbiome endpoints in clinical trials are the most powerful if the findings integrate well into the broader clinical context. This may be difficult to justify where microbiome diversity shifts without functional outcomes.
Study design must reflect the intended claim and target population: Randomized, double-blind, and placebo-controlled design can be the optimal for getting reliable human data. The overall experimental approach, population studied, the duration of the trial, control groups, and what endpoints are evaluated should be consistent with the claims that a sponsor aims to make.
What Sponsors Should Consider Before Starting a Microbiome Study
Before permitting any microbiome clinical research, sponsors should work through these questions:
What health area does the product aim to support?
Defining the target area, whether it is gut-immune, gut-brain, skin, vaginal or metabolic, determines the relevant endpoints and the necessary regulatory frameworks.
What claim does the sponsor want to substantiate?
The study design should follow the intended claim.
Is the target population clearly defined?
Healthy adults, peri-menopausal women, adults with specific conditions and trained athletes make the population that determines the recruitment strategy, ethical requirements and how the results are interrupted.
Which microbiome sample type is relevant?
Gut, skin, vaginal sample collections must be matched to the product’s mechanism and the area of intended benefit.
Which clinical endpoints should be included alongside microbiome analysis?
Microbiome endpoints in clinical trials are effective when paired with functional or symptomatic outcomes that are relevant to the product claim.
What confounders need to be controlled?
Diet, antibiotic use, physical activity and menstrual cycle stage can all influence microbiome composition.
How Atlantia Supports Microbiome Clinical Research
Atlantia Clinical Trials can help sponsors in transforming emerging opportunities in microbiome research into robust human evidence. We have expertise in performing complete microbiome clinical trials for sponsors, which includes:
- Microbiome‑focused study design corresponding to specific claims
- Endpoint and biomarker planning to make sure that the microbiome data align with solid clinical outcomes
- Participant recruitment and retention for various groups of people
- In‑house clinical sites in Cork and Chicago for conducting studies in the EU and US
- Stool, skin, vaginal, and other biological sample collection workflows with established handling protocols for the microbiome
- Various types of trials (on-site, remote, hybrid, multicenter) depending on logistics and regulatory requirements
- Expertise in the product categories such as nutraceuticals, functional foods, cosmetics, medical devices, and pharmaceuticals
- End‑to‑end delivery, from protocol development and ethics submissions through data management, analysis, and reporting.
Conclusion: The Future of Microbiome Research Is Broader Than the Gut
World Microbiome Day emphasizes how fast microbiome science is changing our concepts of human health. Microbiome research beyond gut health is informing new approaches in immune function, mental health, cosmodermatics, metabolic health, women’s health, and human performance. From a sponsor’s perspective, the most appealing emerging opportunities in microbiome research are well-designed microbiome clinical trials that combine strong clinical endpoints and high-quality microbiome data. The increasing need for evidence means that working together with experienced microbiome clinical research specialists such as Atlantia will allow sponsors to create innovative and scientifically justified microbiome-based products.